Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CARCIK-CD19 in Relapsed/Refractory B-cell NHL and CLL
NCT05869279Phase 2Recruiting
- Sponsor
- Fondazione Matilde Tettamanti
- Start
- Dec 2023
- Primary completion
- Sep 2026
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of CARCIK-CD19 in B-cell non-Hodgkin lymphoma, chronic lymphocytic leukemia (CLL), sponsored by Fondazione Matilde Tettamanti. Started Dec 2023; status: recruiting.
02
Drugs
CARCIK-CD19
03
Conditions
B-cell non-Hodgkin lymphomachronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT05869279.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05869279.